A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.

Christopher CultraraChristopher UhlKenneth KirbyEssam Abed ElrazaqAmelia ZellanderDavid W AndrewsCharles B ScottLorenzo GalluzziMark A ExleyJenny Zilberberg

Published in: Journal for immunotherapy of cancer (2023)

These results support treatment with IGV-001 to induce clinically relevant ICD-driven anticancer immune responses in patients with GBM.

Keyphrases

immune response
cell death
dendritic cells
rheumatoid arthritis
combination therapy
inflammatory response
signaling pathway
cell proliferation
smoking cessation